By Sam Reisman ( November 9, 2026, 5:33 PM EST) -- Pharmaceutical company Compass Pathways announced Monday that it had submitted to the U.S. Food and Drug Administration a new drug application to treat treatment-resistant depression with psilocybin, the primary compound in psychoactive mushrooms....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.